AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of AZD8931 in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT00637039
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Open Label Trial to Assess Iressa in Prostate Cancer Patients
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00635856
Open-Label Extension of Other SZ1839 (Iressa) Trials
Phase 3
Completed
- Conditions
- Cancer
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00635973
Second Line Breast Cancer Trial
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 588
- Registration Number
- NCT00635713
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
- Conditions
- Adenocarcinoma of the Prostate
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2008-06-11
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00636259
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 734
- Registration Number
- NCT00634712
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00635414
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6268
- Registration Number
- NCT00634400
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00634309
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2515
- Registration Number
- NCT00635492
- Locations
- 🇸🇪
Research Site, Vastervik, Sweden
🇩🇪Research, Birkenfeld, Germany
© Copyright 2025. All Rights Reserved by MedPath